Key Takeaways
Hangzhou Tigermed Consulting Co. (3347.HK) shares fell 7.4 percent after the company reported a 70.4 percent drop in first-quarter net profit, a figure that masked healthy underlying growth in its core business.
The results were skewed by a non-operational accounting item, according to a UBS report that reiterated an “Outperform” rating on the company with a target price of HKD 56.1.
Tigermed’s revenue for the first quarter of 2026 increased 15.2 percent year-over-year to RMB 1.8 billion, meeting analyst expectations. However, net profit attributable to shareholders fell to RMB 49.04 million. Excluding one-off items, the company’s adjusted net profit grew 17.7 percent from the prior year to RMB 120 million.
The significant divergence between reported and adjusted profit stems from a RMB 195 million fair value gain recorded by the company's consolidated investment funds. This gain increased the profit attributable to non-controlling interests, which in turn reduced the net profit available to Tigermed’s own shareholders.
The market reacted sharply to the headline number, with Tigermed’s stock opening 4.55 percent lower and hitting a low of HKD 39.78 during the session. The stock last traded at HKD 40.76, down 7.36 percent, with turnover of HKD 116 million.
The accounting technicality overshadowed what was otherwise a solid quarter of operational performance. The 17.7 percent growth in adjusted net profit suggests the company's main clinical research services business continues to expand.
The sharp selloff highlights investor sensitivity to headline earnings misses, even when driven by non-cash, non-operational factors. Investors will now watch the company's second-quarter results to confirm that underlying business momentum remains on track.
This article is for informational purposes only and does not constitute investment advice.
